Analysts have been eager to weigh in on the Technology sector with new ratings on Semtech (SMTC – Research Report), Pagaya Technologies Ltd (PGY – Research Report) and Broadridge Financial Solutions (BR – Research Report).
Semtech (SMTC)
In a report issued on January 17, Anthony Stoss from Craig-Hallum assigned a Buy rating to Semtech. The company’s shares closed last Monday at $21.53.
According to TipRanks.com, Stoss is a 5-star analyst with an average return of
Currently, the analyst consensus on Semtech is a Strong Buy with an average price target of $29.63, which is a 37.7% upside from current levels. In a report issued on January 2, Stifel Nicolaus also maintained a Buy rating on the stock with a $26.00 price target.
See today’s best-performing stocks on TipRanks >>
Pagaya Technologies Ltd (PGY)
Benchmark Co. analyst Michael Legg reiterated a Buy rating on Pagaya Technologies Ltd on January 17 and set a price target of $6.00. The company’s shares closed last Monday at $1.14.
According to TipRanks.com, Legg is ranked #1227 out of 8673 analysts.
Pagaya Technologies Ltd has an analyst consensus of Strong Buy, with a price target consensus of $3.25, which is a 195.5% upside from current levels. In a report issued on January 17, JMP Securities also maintained a Buy rating on the stock with a $2.25 price target.
Broadridge Financial Solutions (BR)
D.A. Davidson analyst Peter Heckmann maintained a Hold rating on Broadridge Financial Solutions on January 17 and set a price target of $180.00. The company’s shares closed last Monday at $206.15, close to its 52-week high of $207.29.
According to TipRanks.com, Heckmann is a 4-star analyst with an average return of
Broadridge Financial Solutions has an analyst consensus of Hold, with a price target consensus of $192.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SMTC:
- Semtech price target raised to $30 from $25 at Northland
- Semtech price target raised to $26 from $22 at Stifel
- Short Report: Eyepoint Pharmaceuticals bears cut bait after Phase 2 trial data
- Semtech price target lowered to $25 from $32 at Northland
- Semtech price target lowered to $22 from $24 at Stifel
